---
document_datetime: 2025-10-20 12:35:28
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/onureg-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: onureg-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.337641
conversion_datetime: 2025-12-29 20:35:35.245931
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Onureg

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                          |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------|
| Variation type IB /  | C.I.3 Change(s) in the Summary of Product | 14/10/2025                          |                                             | SmPC and PL                      | To include the adverse reaction 'differentiation |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291593                | Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.z Other variation - Accepted To include the adverse reaction 'differentiation syndrome' in sections 4.4 and 4.8 of the SmPC following the assessment in EMEA/H/C/PSUSA/00010935/202405. The package leaflet is updated accordingly. In addition the MAH has amended the wording for tabulated list of adverse reactions in section 4.8 of the SmPC.   |            |    | syndrome' in sections 4.4 and 4.8 of the SmPC following the assessment in EMEA/H/C/PSUSA/00010935/202405. The package leaflet is updated accordingly. In addition the MAH has amended the wording for tabulated list of adverse reactions in section 4.8 of the SmPC.   |
|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Article 61(3) / EMA/N/0000245924 | Update of the package leaflet to introduce a list of local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/02/2025 | PL |                                                                                                                                                                                                                                                                         |